Release Date: 23-Jan-2025
IBI323 is an innovative LAG-3/PD-L1 bispecific antibody being developed by Innovent Biologics, designed to enhance immune system activity against tumors. This bispecific antibody targets two crucial immune checkpointsandmdash;LAG-3 (lymphocyte-activation gene 3) and PD-L1 (programmed death-ligand 1)andmdash;both of which are involved in immune suppression within the tumor microenvironment. By simultaneously inhibiting LAG-3’s binding to major histocompatibility complex (MHC) class II and PD-L1’s binding to PD-1, IBI323 aims to relieve the immune evasion mechanisms tumors use to avoid detection and destruction by T cells.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
LAG-3 and PD-L1 play vital roles in immune regulation. LAG-3 is expressed on activated T cells and inhibits their activation when it binds to MHC class II molecules, reducing T cell-mediated immune responses. PD-L1, on the other hand, is often expressed on tumor cells and binds to the PD-1 receptor on T cells, leading to immune suppression and allowing tumors to escape immune surveillance. By targeting both of these checkpoints, IBI323 prevents the suppression of T cells, potentially enhancing their ability to recognize and kill tumor cells.
The dual-action of IBI323 also works by tethering LAG-3-positive T cells to PD-L1-positive tumor cells. This tethering effect can facilitate the formation of more effective immune synapses, leading to stronger T cell-mediated tumor cell killing. By addressing two major immune checkpoints simultaneously, IBI323 could provide a more powerful anti-tumor response compared to therapies targeting just one pathway.
Currently, IBI323 is undergoing Phase 2 clinical trials in combination with bevacizumab and platinum-based chemotherapy for the treatment of ALK-rearranged non-small cell lung cancer (NSCLC) in patients who have failed first-line treatment with alectinib. This trial aims to assess the efficacy and safety of IBI323 in overcoming resistance in these patients, offering a promising treatment strategy for a challenging form of cancer. If successful, IBI323 could become an important addition to the cancer immunotherapy landscape.